
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington, D.C. - Elective dermatologic surgeries in children have been enhanced by new technologies, new clinical research, new anesthesia, and new therapies. A five-member panel discussion held at the annual meeting of the American Academy of Dermatology highlighted many of these advances and provided practical tips for treating children over the age of 7.